Chief Executive Officer
Trey Martin has more than 25 years of executive leadership experience in life sciences operations, engineering, sales, product development, and marketing. Prior to assuming the CEO role in July 2023, Mr. Martin served as President, Biologics Safety Testing at Maravai from December 2022 to July 2023. Previously, he was Senior Vice President, Genomic Medicines at Danaher Corporation, where he oversaw new business creation in the areas of mRNA, gene editing and gene therapy. Mr. Martin originally joined Danaher with the acquisition of Integrated DNA Technologies (IDT) in 2018, serving as President of IDT. Prior to the acquisition by Danaher, Mr. Martin held positions of increasing responsibility over his more than two decades of tenure at IDT and contributed to the consistent growth and competitiveness of the company’s genomic solutions business through directing organic and inorganic growth investments, including product portfolio and service capability expansions, strategic customer collaborations and global M&A in the nucleic acid space. Mr. Martin holds a bachelor’s degree in biochemistry from the University of Iowa.
Executive Vice President and Chief Financial Officer
Kevin Herde is an experienced financial management executive with over 25 years of experience in finance, accounting and general management focusing on diagnostics, biopharmaceutical development and technology. Mr. Herde joined Maravai LifeSciences from Sorrento Therapeutics, where he was most recently Executive Vice President and Chief Financial Officer. Prior to Sorrento Therapeutics, Mr. Herde served as Vice President of Global Blood Screening at Hologic. There he worked in conjunction with the company’s strategic partners at Grifols and Novartis, managing a multinational business providing molecular diagnostics solutions to improve blood safety. Mr. Herde also worked with Carl Hull and Eric Tardif as Vice President, Finance and Corporate Controller for Gen-Probe prior to its acquisition by Hologic in 2012. Mr. Herde is a CPA and began his career with KPMG. Mr. Herde holds a B.B.A. in business administration from University of San Diego.
Pete Leddy, PhD
Executive Vice President and Chief Administrative Officer
Pete Leddy has over 30 years of experience leading growth and change across a wide variety of businesses, and specifically in scaling global healthcare companies. Throughout 2022, Pete worked as a consultant to Maravai on a number of issues related to organizational design, compensation and retention before joining the Company as CAO. Previously, Pete served as Chief Human Resources Officer at Berkeley Lights, Chief People Officer at dosist, Executive Vice President, Global Human Resources and Corporate Integrity at Nuvasive and Chief Human Resources Officer at Life Technologies and Invitrogen. Earlier in his career he held a variety of executive and human resource positions at Dell, Promus Hotel Corp. and PepsiCo. He received his B.A. in Psychology from Creighton University and his M.S. and Ph.D. degrees in industrial/organizational psychology from the Illinois Institute of Technology.
Executive Vice President, Secretary and General Counsel
Kurt Oreshack joined Maravai LifeSciences as General Counsel in November 2020. Prior to joining Maravai, Mr. Oreshack was a partner at Breakwater Law Group, practicing in the field of corporate and securities law. Prior to joining Breakwater Law Group, he was the General Counsel of Human Longevity, and previously practiced law individually and as General Counsel in Residence at Gunderson Dettmer Stough Villeneuve Franklin & Hachigian. Mr. Oreshack received a J.D. from the University of Notre Dame Law School and a B.A. from Loyola University Chicago. He is a member of the State Bar of California.
Kate Broderick, PhD
Chief Innovation Officer
Dr. Kate Broderick has more than 15 years of experience in the life science industry. A recognized vaccine expert, Dr. Broderick has a broad background in device and product development in the DNA therapeutic and drug delivery field. Prior to joining Maravai in 2022, Dr. Broderick held roles of increasing responsibility at Inovio Pharmaceuticals, most recently as Senior Vice President, R&D. Dr. Broderick has served as a principal investigator for a variety of grants and awards from government agencies and non-profits, including the National Institutes of Health. She received her PhD from the University of Glasgow in Scotland and completed her post-doctoral research at the University of California, San Diego.
Chief Commercial Officer
Becky Buzzeo has more than 20 years of commercial leadership experience. Before joining Maravai, in October of 2022, she was the Vice President and General Manager, Advanced Therapies, at Thermo Fisher Scientific, where she oversaw CDMO services for plasmid DNA, cell therapy and mRNA. Prior to that, Mrs. Buzzeo led commercial operations at Brammer Bio and held commercial roles of increasing responsibility at Patheon Biologics and Life Technologies, before its acquisition by Thermo Fisher in 2014. Mrs. Buzzeo holds a B.S. in biology from Slippery Rock University of Pennsylvania.
Chief Operating Officer, Biologics Safety Testing
Christine Dolan has served as the Chief Operating Officer of Maravai LifeSciences’ Biologics Safety Testing business segment since October 2017. Prior to joining Maravai, Ms. Dolan held several operational and business leadership roles including Senior Vice President of Product Development, VP of Global Operations and VPGM of Development and Analytical Services at Catalent Pharma Solutions. Prior to joining Catalent Pharma Solutions, she was Director of Nuclear Operations and Global Quality Control at GE Healthcare and Amersham Health. Dolan holds a B.S. in biology from Lenoir-Rhyne College.
Executive Vice President, Nucleic Acid Products
Drew Burch has over 30 years of strategic, operational, commercial and financial experiences in the life sciences industry. Prior to joining Maravai, he was President, Softgels at Thermo Fisher Scientific, where he led the division’s CDMO services in the U.S. and Europe. He also held multiple leadership positions across other Thermo Fisher Scientific’s business segments, including Instrument and Enterprise Services and European Drug Product Division as President, and Life Sciences Solutions as Vice President, Strategy and Business Development. Previously, Mr. Burch worked as an advisor to healthcare companies on M&A during his tenures at Barclays Capital, Lehman Brothers and Merrill Lynch & Co. He holds an MBA from Stanford University Graduate School of Business and a B.A. in Economics and Political Science from Yale University.
Executive Vice President, Enzymes
Chris Benoit joined Maravai in 2023 through the acquisition of Alphazyme. Mr. Benoit has more than 25 years of scientific experience in the development, manufacture, and QC of molecular biology tools. In 2006, Mr. Benoit co-founded Enzymatics, Inc., a life science enzyme manufacturer, quickly growing the company’s global recognition until it was acquired by QIAGEN in 2014. In 2018, Mr. Benoit co-founded Alphazyme, a premier provider of customer, industrial-scale, molecular biology enzymes. Mr. Benoit holds his B.S. in biochemistry from the University of Massachusetts Amherst.
Vice President, Strategy and Business Development
Deb Barbara joined Maravai in April 2022. Ms Barbara has over 30 years of experience in a variety of business development roles, most recently as Senior Director/General Manager, Nucleic Acid Therapeutics for Thermo Fisher Scientific. Prior to that, she was Vice President, Business Development at Strategic Diagnostics (SDIX). Prior to SDIX, Ms. Barbara was Vice President, Business Development and Licensing at Gene Logic/Ore Pharmaceuticals. Prior to Ore Pharmaceuticals, she spent seven years at Johns Hopkins University with her last role as Senior Director, Business/Technology Development, and 11 years at Amersham Life Science in progressive account management roles. Ms. Barbara holds an MBA from Loyola University Maryland and a B.S. in Biochemistry and Molecular Biology from the University of Maryland Baltimore County.
Vice President, Marketing
Doreen Pippen joined Maravai LifeSciences as Vice President, Marketing in January 2021 and has extensive experience in market development, product management, strategy and marketing leadership for scientific consumables and instrument services. She was most recently Senior Vice President of Business Development and Product Leader at Science and Medicine Group. She also held several management roles at Thermo Fisher Scientific in customer loyalty, global service and support, as well as market development and product management for the Protein Analysis, Epigenetics and qPCR portfolios. Ms. Pippen holds an MBA from National University and a B.A. in biology from the University of San Diego.